EUCTR2011-000876-33-FI进行中（未招募）不适用
A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy toddlers, previously primed with three doses of the same vaccine in study 113948 (DTPA-HBV-IPV-124 PRI). - DTPA-HBV-IPV-125 BST:124
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects who participated in the study 113948 (DTPA-HBV-IPV-124 PRI) and received three doses of the new or licensed DTPa-HBV-IPV/Hib study vaccine.
- •- A male or female child between, and including, 12 and 15 months of age at the time of the booster vaccination.
- •- Subjects who the investigator believes that parent(s)/ LAR(s) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visit).
- •- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •- Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 720
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Child in care.
- •- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- •- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose. For corticosteroids, this will mean prednisone = 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •- Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period.
- •- Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •- Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib vaccination or disease since the conclusion visit of study 113948 (DTPA-HBV-IPV-124 PRI).
- •- Serious chronic illness.
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •- History of any neurological disorders or seizures.
- •- Administration of immunoglobulins and/or any blood products within the 3 months preceding the booster dose of study vaccine or planned administration during the study period.
- •- Occurrence of any of the following events following previous administration of the study vaccine constitutes an absolute contraindication to further dosing.
- •Anaphylactic or other hypersensitivity reaction.
- •Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
- •Temperature of = 40.0°C (axillary) or 40.5°C (rectal) within 48 hours of vaccination, not due to another identifiable cause.
- •Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- •Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting = 3 hours.
- •Seizures with or without fever occurring within 3 days of vaccination.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •- Acute disease and/or fever at the time of enrolment.
- •Fever is defined as temperature = 37.5°C on oral, axillary or tympanic setting, or = 38.0° on rectal setting.
- •Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
不适用
Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine.EUCTR2011-000876-33-Outside-EU/EEAGlaxoSmithKline Biologicals657
进行中（未招募）
不适用
A phase II, multi-centre, single blind study to evaluate the safety, tolerability and explore the efficacy of 8.0 mg ASM8 inhaled daily for 14 days in adult subjects with moderate to severe asthma - Safety & Tolerability of 8mg ASM8 in moderate to severe asthmaticsmoderate to severe asthmaMedDRA version: 13.1Level: LLTClassification code 10003638Term: Atopic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 13.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-000126-30-GBPharmaxis Ltd15
进行中（未招募）
1 期
A study to evaluate whether 2 concentrations of THR-317 safely work to treat diabetic macular oedemaEUCTR2016-002100-25-CZThromboGenics NV50
进行中（未招募）
1 期
A study to evaluate whether 2 concentrations of THR-317 safely work to treat diabetic macular oedemaEUCTR2016-002100-25-SKThromboGenics NV50
进行中（未招募）
1 期
A study to evaluate whether 2 concentrations of THR-317 safely work to treat diabetic macular oedemadiabetic macular oedema (DME)MedDRA version: 20.0Level: LLTClassification code 10057915Term: Diabetic macular oedemaSystem Organ Class: 100000015084MedDRA version: 20.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000015084EUCTR2016-002100-25-HUThromboGenics NV50